logo-loader
viewValeo Pharma Inc.

Valeo Pharma applies to Health Canada to licence immune system support product Hesperco

Valeo Pharma (CSE: VPH) President and CEO Steve Saviuk joined Steve Darling from Proactive Vancouver with news the company has entered into a collaboration and licensing agreement with Ingenew Pharma for the development, manufacture and commercialization of Hesperco. Saviuk tells Proactive more about the deal and more about Hesperco and also when they are hoping to hear from Health Canada.

Quick facts: Valeo Pharma Inc.

Price: 1.43 CAD

CSE:VPH
Market: CSE
Market Cap: $83.04 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics remain optimistic about US commercialisation of Accrufer...

Shield Therapeutics PLC (LON:STX) Chief Executive Tim Watts joins Proactive London's Katie Pilbeam to discuss their financial and operational update. Watts highlights the European sales volumes of its breakthrough iron deficiency drug Feraccru which grew by 70% year-on-year. He...

2 days, 10 hours ago

2 min read